Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tolloid-like protein 2 (TLL2)
- Target
- TLL2
- Molecular classification
- Enzyme, Metalloprotease (specifically, astacin-like zinc-dependent metalloprotease), Metzincin metallopeptidase family
01
Overview
Tolloid-like protein 2 (TLL2) is a zinc-dependent astacin metalloprotease belonging to the metzincin family and the BMP1/tolloid-like subfamily. It is involved in the proteolytic processing necessary for extracellular matrix formation and tissue morphogenesis, with a substrate specificity distinct from other family members such as BMP1 and TLL1. Unlike these enzymes, a similar protein in mice does not cleave procollagen C-propeptides or chordin. TLL2 has been implicated as a therapeutic target for conditions related to excessive fibrosis and muscle wasting, although there are no approved drugs targeting TLL2 as of now. Genetic studies suggest additional roles in neurobehavioral regulation and psychiatric disorders such as bipolar disorder, and a genetic variant is associated with poorer outcomes in melanoma. TLL2 is encoded by the TLL2 gene (GeneCards: TLL2, NCBI Gene ID: 7093, UniProt ID: Q9Y6L7).
- Other names
- Tolloid-like protein 2TLL2KIAA0932tolloid like 2
02
Biological functions
Proteolytic processing involved in extracellular matrix formation and morphogenesisRegulation of neurobehavioral pathwaysCalcium ion bindingCollagen chain trimerizationMetallopeptidase activity
03
Disease associations
Cancer (Hematologic cancer, Glottis squamous cell carcinoma)Psychiatric disorders (potential role in bipolar disorder susceptibility)Cutaneous melanoma (prognostic biomarker)Possibly muscle wasting and excessive fibrosis (preclinical context)
04
Safety considerations
As a regulator of tissue morphogenesis and extracellular matrix dynamics, safety concerns for drug targeting may include impaired wound healing, fibrosis modulation, and possible effects on neurobehavioral processes
05
Biomarkers
rs10882807 T>C (a genetic variant predicting poorer survival in cutaneous melanoma)
Beyond the preview
Go deeper on Tolloid-like protein 2 (TLL2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tolloid-like protein 2 (TLL2).